Current breast cancer therapies are based on chemotherapeutics that act as selective oestrogen receptor modulators (SERMs) (e.g. Tamoxifen) or inhibitors of the aromatase enzyme complex (e.g. Letrozole or Anastrozole).8–10. This evidence concerns the gene CYP19A1 and breast carcinoma.